JP2012520829A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012520829A5 JP2012520829A5 JP2012500012A JP2012500012A JP2012520829A5 JP 2012520829 A5 JP2012520829 A5 JP 2012520829A5 JP 2012500012 A JP2012500012 A JP 2012500012A JP 2012500012 A JP2012500012 A JP 2012500012A JP 2012520829 A5 JP2012520829 A5 JP 2012520829A5
- Authority
- JP
- Japan
- Prior art keywords
- delivery system
- drug delivery
- transdermal drug
- adhesive
- transdermal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000013271 transdermal drug delivery Methods 0.000 claims description 32
- 229960003425 tirofiban Drugs 0.000 claims description 26
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 claims description 26
- 239000000463 material Substances 0.000 claims description 19
- 239000000853 adhesive Substances 0.000 claims description 18
- 230000001070 adhesive effect Effects 0.000 claims description 18
- 238000003556 assay Methods 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 11
- 239000011159 matrix material Substances 0.000 claims description 10
- 239000003961 penetration enhancing agent Substances 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 10
- 239000004615 ingredient Substances 0.000 claims description 8
- 238000012423 maintenance Methods 0.000 claims description 6
- 230000001629 suppression Effects 0.000 claims description 6
- 238000012377 drug delivery Methods 0.000 claims description 5
- 230000037317 transdermal delivery Effects 0.000 claims description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical group CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 4
- 239000003522 acrylic cement Substances 0.000 claims description 4
- 125000005233 alkylalcohol group Chemical group 0.000 claims description 4
- 239000012876 carrier material Substances 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 4
- 235000020778 linoleic acid Nutrition 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 3
- 230000009257 reactivity Effects 0.000 claims description 3
- 238000012292 receptor occupancy assay Methods 0.000 claims description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 2
- 206010002388 Angina unstable Diseases 0.000 claims description 2
- 108010056764 Eptifibatide Proteins 0.000 claims description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 claims description 2
- 206010060840 Ischaemic cerebral infarction Diseases 0.000 claims description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 2
- 208000007814 Unstable Angina Diseases 0.000 claims description 2
- 125000005396 acrylic acid ester group Chemical group 0.000 claims description 2
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 2
- -1 aliphatic alcohols Chemical class 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 229960004468 eptifibatide Drugs 0.000 claims description 2
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 2
- 125000005397 methacrylic acid ester group Chemical group 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 230000000250 revascularization Effects 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 238000004448 titration Methods 0.000 claims description 2
- 238000013146 percutaneous coronary intervention Methods 0.000 claims 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 235000019441 ethanol Nutrition 0.000 claims 1
- 239000008240 homogeneous mixture Substances 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16113209P | 2009-03-18 | 2009-03-18 | |
| US61/161,132 | 2009-03-18 | ||
| US24002109P | 2009-09-04 | 2009-09-04 | |
| US61/240,021 | 2009-09-04 | ||
| US25968309P | 2009-11-10 | 2009-11-10 | |
| US61/259,683 | 2009-11-10 | ||
| PCT/CA2010/000373 WO2010105342A1 (en) | 2009-03-18 | 2010-03-18 | Transdermal pharmaceutical preparation and administration of tirofiban |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015095030A Division JP2015187115A (ja) | 2009-03-18 | 2015-05-07 | チロフィバンの経皮用医薬製剤および投与 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012520829A JP2012520829A (ja) | 2012-09-10 |
| JP2012520829A5 true JP2012520829A5 (enExample) | 2013-02-07 |
Family
ID=42739074
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012500012A Pending JP2012520829A (ja) | 2009-03-18 | 2010-03-18 | チロフィバンの経皮用医薬製剤および投与 |
| JP2015095030A Pending JP2015187115A (ja) | 2009-03-18 | 2015-05-07 | チロフィバンの経皮用医薬製剤および投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015095030A Pending JP2015187115A (ja) | 2009-03-18 | 2015-05-07 | チロフィバンの経皮用医薬製剤および投与 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20120029447A1 (enExample) |
| EP (1) | EP2408440B1 (enExample) |
| JP (2) | JP2012520829A (enExample) |
| CN (2) | CN105311003A (enExample) |
| AU (1) | AU2010225405B2 (enExample) |
| BR (1) | BRPI1009313A2 (enExample) |
| CA (1) | CA2755569A1 (enExample) |
| RU (1) | RU2539398C2 (enExample) |
| WO (1) | WO2010105342A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114984330A (zh) * | 2022-06-07 | 2022-09-02 | 新乡医学院 | 一种兼具抗凝与抗钙化的脱细胞血管支架及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5271940A (en) * | 1989-09-14 | 1993-12-21 | Cygnus Therapeutic Systems | Transdermal delivery device having delayed onset |
| NZ239846A (en) * | 1990-09-27 | 1994-11-25 | Merck & Co Inc | Sulphonamide derivatives and pharmaceutical compositions thereof |
| US6117842A (en) * | 1998-03-09 | 2000-09-12 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| DE10033853A1 (de) * | 2000-07-12 | 2002-01-31 | Hexal Ag | Transdermales therapeutisches System mit hochdispersem Siliziumdioxid |
| DE10060852A1 (de) * | 2000-12-06 | 2002-06-20 | Hexal Ag | Absorptionsmittel und Kanalbildner enthaltende wirkstoffundurchlässige Deckschicht oder abziehbare Schutzschicht eines transdermalen therapeutischen Systems |
| US20040072750A1 (en) * | 2001-05-03 | 2004-04-15 | David Phillips | Compounds and methods for the modulation of CD154 |
| US6770660B2 (en) * | 2002-05-06 | 2004-08-03 | Artery Llc | Method for inhibiting platelet aggregation |
| AU2003277398A1 (en) * | 2002-10-15 | 2004-05-04 | The University Of Tennessee Research Foundation | Methods for assessment of platelet aggregation |
| AR049847A1 (es) * | 2004-07-29 | 2006-09-06 | Merck & Co Inc | Inhibidores de los canales de potasio |
-
2010
- 2010-03-18 US US13/257,009 patent/US20120029447A1/en not_active Abandoned
- 2010-03-18 CN CN201510756414.1A patent/CN105311003A/zh active Pending
- 2010-03-18 EP EP10753026.3A patent/EP2408440B1/en not_active Not-in-force
- 2010-03-18 AU AU2010225405A patent/AU2010225405B2/en not_active Ceased
- 2010-03-18 CA CA2755569A patent/CA2755569A1/en not_active Abandoned
- 2010-03-18 RU RU2011138305/15A patent/RU2539398C2/ru not_active IP Right Cessation
- 2010-03-18 BR BRPI1009313A patent/BRPI1009313A2/pt not_active IP Right Cessation
- 2010-03-18 WO PCT/CA2010/000373 patent/WO2010105342A1/en not_active Ceased
- 2010-03-18 CN CN201080021932.4A patent/CN102427806B/zh not_active Expired - Fee Related
- 2010-03-18 JP JP2012500012A patent/JP2012520829A/ja active Pending
-
2013
- 2013-12-11 US US14/102,724 patent/US20140100537A1/en not_active Abandoned
-
2015
- 2015-05-07 JP JP2015095030A patent/JP2015187115A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI435737B (zh) | 經皮遞送醫藥化合物的方法及其組成物 | |
| US9295655B2 (en) | Fentanyl transdermal patch | |
| JP2015500329A5 (enExample) | ||
| US20170189347A1 (en) | Transdermal delivery system | |
| JP5820469B2 (ja) | プロピニルアミノインダンの経皮組成物 | |
| US20140242151A1 (en) | Adhesive skin patch | |
| KR20040079924A (ko) | 피부 또는 경피 치료 시스템용 부착 및 결합제 | |
| ES2745154T3 (es) | Sistema de tratamiento transdérmico que contiene buprenorfina y un alfa-hidroxiácido | |
| KR101054317B1 (ko) | 리바스티그민을 함유하는 경피흡수제제 | |
| US20170071880A1 (en) | Selegiline transdermal system | |
| TWI648072B (zh) | 貼附製劑 | |
| JP2012520829A5 (enExample) | ||
| RU2432179C2 (ru) | Фармацевтический препарат абсорбционного типа для чрезкожного введения | |
| KR950015055B1 (ko) | 활성성분으로서 노르슈도에페드린을 함유하는 경피 치료용 시스템 | |
| US20140370077A1 (en) | Transdermal drug delivery system containing fentanyl | |
| JP2015187115A (ja) | チロフィバンの経皮用医薬製剤および投与 | |
| US5965155A (en) | Transdermal therapeutic system with pentylene tetrazol as active substance | |
| BR112020000391B1 (pt) | Sistema terapêutico transdérmico para administração cutânea de fampridina, seu uso e processo de produção | |
| HUP0104950A2 (en) | Composition containing glycerol trinitrate, method for producing said composition and use of the same | |
| KR20060052931A (ko) | 경피용 와파린-포함 전달 시스템 | |
| TWI745577B (zh) | 經皮吸收製劑 | |
| RS65194B1 (sr) | Medicinski flaster sa sporim otpuštanjem | |
| WO2014159778A1 (en) | Transdermal drug delivery system containing fentanyl | |
| JP2019034905A (ja) | デヒドロ酢酸含有経皮吸収製剤 | |
| BR112020000391A2 (pt) | fampridina tts |